Company Filing History:
5 out of 505 
4 out of 1,209 
3 out of 894 
Years Active: 2005-2012
Title: Michael C Heinrich: Innovator in Cancer Treatment
Introduction
Michael C Heinrich is a prominent inventor based in Lake Oswego, OR (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 5 patents, Heinrich's work focuses on identifying and treating individuals with specific protein tyrosine kinase associated disorders.
Latest Patents
Heinrich's latest patents include groundbreaking methods for identifying and treating individuals exhibiting mutant kit protein. This invention relates to methods for diagnosing and treating patients who may have developed resistance to kinase inhibitors, such as imatinib, due to gain-of-function mutations in KIT tyrosine kinase. Another notable patent involves platelet-derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutations. This disclosure provides variants of tyrosine kinase proteins and nucleic acids linked to neoplasms and cancer progression, along with methods for diagnosis, prognosis, and the development of new therapeutic agents.
Career Highlights
Throughout his career, Heinrich has worked with esteemed institutions, including Oregon Health & Science University and Dana-Farber Cancer Institute Inc. His research has significantly advanced the understanding of cancer biology and treatment options.
Collaborations
Heinrich has collaborated with notable professionals in the field, including George Daniel Demetri and Jonathan A Fletcher. These collaborations have further enriched his research and contributed to the development of innovative treatment strategies.
Conclusion
Michael C Heinrich's contributions to cancer treatment through his patents and research have made a lasting impact in the medical field. His work continues to inspire advancements in the diagnosis and treatment of cancer-related disorders.